A phase 2 investigator sponsored study of Pelareorep in combination with pembrolizumab (KEYTRUDA®) in patients with relapsed metastatic, advanced adenocarcinoma of the pancreas.

Trial Profile

A phase 2 investigator sponsored study of Pelareorep in combination with pembrolizumab (KEYTRUDA®) in patients with relapsed metastatic, advanced adenocarcinoma of the pancreas.

Planning
Phase of Trial: Phase II

Latest Information Update: 17 May 2018

At a glance

  • Drugs Pelareorep (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 May 2018 According to the Oncolytics Biotech media release, final study design and other details of this study will be announced upon enrollment of the first patient, expected in the third quarter 2018.
    • 17 May 2018 According to the Oncolytics Biotech media release, this study run by the principal investigator Dr. Devalingham Mahalingam and will be conducted at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
    • 14 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top